The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Plasma AR and abiraterone-resistant prostate cancer
Open accessAbstract
Androgen receptor mutations and amplifications in circulating tumor DNA provide clues to prostate cancer drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 2×
“Selection of CRPC patients for evaluation of AR genomic aberrations We selected patients starting standard-of-care abiraterone between January 2011, after the reporting of the abiraterone phase 3 regulatory trial (1), and October 2014.”
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Metastatic biopsies have provided important information on the emergence of resistance mutations in other diseases, such as EGFRmutations in lung cancer (5).”
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,388
The Ka/Ks ratio: diagnosing the form of sequence evolution
Hurst, L. D. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(02)02722-1 · Cited by 1,356
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,169
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja, M. J., Savinainen, K., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., & Visakorpi, T. (2001) · PubMed · Cited by 774
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., Anderson, S. A., McConeghy, B., Shukin, R., Bazov, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2666 · Cited by 478
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Heitzer, E., Ulz, P., Belic, J., Gutschi, S., Quehenberger, F., Fischereder, K., Benezeder, T., Auer, M., Pischler, C., Mannweiler, S., et al. (2013) · Genome Medicine · doi:10.1186/gm434 · Cited by 357
Tumor clone dynamics in lethal prostate cancer
Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.-S., Pezaro, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009448 · Cited by 340
Self-citationSequence Divergence, Functional Constraint, and Selection in Protein Evolution
Fay, J. C., & Wu, C.-I. (2003) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.4.020303.162528 · Cited by 294
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Beltran, H., Eng, K., Mosquera, J. M., Sigaras, A., Romanel, A., Rennert, H., Kossai, M., Pauli, C., Faltas, B., Fontugne, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1313 · Cited by 288
Self-citationWaltering, K. K., Helenius, M. A., Sahu, B., Manni, V., Linja, M. J., Jänne, O. A., & Visakorpi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0919 · Cited by 228
Chen, E. J., Sowalsky, A. G., Gao, S., Cai, C., Voznesensky, O., Schaefer, R., Loda, M., True, L. D., Ye, H., Troncoso, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1220 · Cited by 182
Detecting predictive androgen receptor modifications in circulating prostate cancer cells
Steinestel, J., Luedeke, M., Arndt, A., Schnoeller, T. J., Lennerz, J. K., Wurm, C., Maier, C., Cronauer, M. V., Steinestel, K., & Schrader, A. J. (2019) · Oncotarget · doi:10.18632/oncotarget.3925 · Cited by 158
Palmberg, C., Koivisto, P. A., Kakkola, L., Tammela, T. L. J., Kallioniemi, O., & Visakorpi, T. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)66935-2 · Cited by 151
Salvi, S., Casadio, V., Conteduca, V., Burgio, S. L., Menna, C., Bianchi, E., Rossi, L., Carretta, E., Masini, C., Amadori, D., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.128 · Cited by 135
Self-citationUnraveling the clonal hierarchy of somatic genomic aberrations
Prandi, D., Baca, S. C., Romanel, A., Barbieri, C. E., Mosquera, J., Fontugne, J., Beltran, H., Sboner, A., Garraway, L. A., Rubin, M. A., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0439-6 · Cited by 104
Self-citationASEQ: fast allele-specific studies from next-generation sequencing data
Romanel, A., Lago, S., Prandi, D., Sboner, A., & Demichelis, F. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0084-2 · Cited by 67
Self-citationDetecting predictive androgen receptor modifications in circulating prostate cancer cells.
Steinestel, J., Luedeke, M., Arndt, A., Schnoeller, T. J., Lennerz, J. K., Maier, C., Cronauer, M. V., Steinestel, K., Boegemann, M., & Schrader, A. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5067 · Cited by 21
Cited by
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citationProtein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Metadata
- Authors
- Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., Bianchini, D., Gurioli, G., Casadio, V., Carreira, S., Goodall, J., Wingate, A., Ferraldeschi, R., Tunariu, N., Flohr, P., De Giorgi, U., de Bono, J. S., Demichelis, F., & Attard, G.
- Venue
- Science Translational Medicine
- Published
- 2015-11-04
- Volume
- 7
- Issue
- 312
- Pages
- 312re10-312re10
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2121098984
- Cited by
- 441
- References
- 32
- FWCI
- 42.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.